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This is the biennial meeting of the
International Forum for the Study of Itch
(IFSI), www.itchforum.net. There were
240 attendees from 17 countries. They
spanned clinical practice, academics,
and patient advocacy, and the opportu-
nity for translation was demonstrated by
the presence of 80 attendees from indus-
try. A large academic neuroscience
contingent was also present. There were
plenary sessions, basic and clinical
tracts, and 60 posters during the two-
and-a-half day meeting. The meeting
program and 160 abstracts are available
at www.itchboston.org and the open
access journal, Acta Dermato-Venereo-
logica, www.medicaljournals.se/acta/.
This report highlights selected aspects
of the congress and the latest advances
in the field.
Plenary talks
Gil Yosipovitch opened the meeting,
elucidating his itch journey as the first
incumbent of the Jeffrey Bernhard Lec-
ture. This journey began as a resident
witnessing the chronic itch suffered by
patients with chronic kidney disease,
culminating in a clinical research career
via extensive collaborative research. He
described the characteristics of different
types of chronic itch across the clinical
spectrum and links these to their neural
basis using functional magnetic reso-
nance imaging.
Earl Carstens from the University of
California, Davis asked whether itch is
a specific sensation distinct from pain.
He answered this question affirmatively
during the Yasushi Kuraishi Lecture. He
demonstrated the existence of subpopu-
lations of specific pruriceptors and
central neurons that signal itch. He
discussed the state-of-the-art research
on neurotransmitters and neuropeptides
by demonstrating the specific involve-
ment in itch of substance P, gastrin-
releasing peptide (GRP), glutamate,
and natriuretic polypeptide B (Nppb).
He noted that the development and use
of multiple antagonists to target the
cognate signaling pathways shows great
promise with respect to fundamental
improvements in the successful treat-
ment of itch.
Clifford Woolf from the Boston Chil-
dren’s Hospital described an exciting
strategy of reversibly silencing specific
subsets of pruritogen- and noxious
stimulus–sensitive sensory axons. This
was accomplished by using QX-314,
a charged sodium channel blocker–
derivative of uncharged lidocaine. QX-
314 cannot cross membranes because
of its positive charge. However, in the
presence of channel agonists that open
pores, such as capsaicin, QX-314 passes
through the pore to reversibly block
these same channels. Woolf suggested
that targeted silencing of activated sen-
sory fibers provides a new avenue for
treatment of itch.
Basic mechanisms of itch
Diana Bautista from University of Cali-
fornia, Berkley presented a new model
in which thymic stromal lymphopoietin
(TSLP) release by keratinocytes, regu-
lated through the ORAI1/NFAT calcium
signaling pathway, activates both pri-
mary afferent neurons and immune cells
to induce inflammatory responses in the
skin and airways leading to the ‘‘atopic
march’’ seen in atopic patients. The data
were subsequently published in Cell.
Sarah Wilson, a postdoctoral fellow in
the Bautista lab, discussed the ion chan-
nel transient receptor potential channel
A1 (TRPA1) in a mouse model of
chronic itch. Her data suggest that
TRPA1 is required for both the transduc-
tion of chronic itch signals to the central
nervous system and pathophysiologic
skin changes observed in chronic itch.
Xinzhong Dong from Johns Hopkins
discussed Mas-related G-protein-coupled
receptor (Mrgprs), a large family of
G-protein-coupled receptors. Mrgprs
comprise the receptors for several
pruritogens, including chloroquine, the
hexapeptide SLIGRL, bovine adrenal
medulla peptide 8-22, and beta-alanine.
He demonstrated that Mrgpr-expressing
neurons in dorsal root ganglia (DRG)–
defined itch-mediating primary sensory
neurons with specific projection pat-
terns in the skin. Mrgprs may thus serve
as novel targets for the treatment of
chronic itch.
Sarina B. Elmariah from Massachu-
setts General Hospital demonstrated that
changes in neural innervation occur in
an ovalbumin epicutaneous–sensitized
mouse model of atopic dermatitis. She
uses in vivo confocal microscopy to
visualize peripheral sensory nerves that
have been fluorescently labeled geneti-
cally. Specific subpopulations of periph-
eral sensory nerves were highly
dynamic throughout the development
of dermatitis and resulted in higher
innervation density. She also demon-
strated that neural blockade during epi-
cutaneous sensitization prevented the
neural changes and resulted in reduced
scratching behavior. These studies sug-
gest that neural changes may precede
immune changes.
Zhou-Feng Chen from Washington
University demonstrated that activation
of the BRAF pathway in NaV1.8þ
(voltage-gated sodium channel) neurons
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of mice causes spontaneous scratching.
These mice have increased ectopic
expression of GRP in DRG neurons
and the GRP receptor (GRPR) and phos-
phorylated extracellular signal-related
kinase in the spinal cord. He demon-
strated that the RAF–MEK–ERK pathway
is an upstream regulator of chronic itch.
This finding suggests that BFAF inhibi-
tors, already of particular interest in the
treatment of certain cancers including
melanoma, may be useful in ameliorat-
ing chronic itch.
Mark Hoon from the National Insti-
tute of Health gave a lecture on NppB.
He demonstrated that NppB knockout
mice exhibit significant reduction in
scratching bouts in response to injection
of different pruritogens, although they
express normal behavioral responses to
thermal and painful stimuli. His work
indicated that NppB-induced itch
requires GRP, whereas GRP-induced
itch does not require NppB. NppB is
thus a functioning upstream of GRP. He
concluded that the NppB receptor and
GRP are co-expressed in dorsal horn
neurons and that NppB is an essential
transmitter and mediator of itch at the
level of the spinal cord.
Sarah Ross from the University of
Pittsburgh presented her work on spinal
B5-I interneurons, which function to
inhibit itch by releasing dynorphin, an
endogenous kappa-opioid (k-opioid)
agonist. She demonstrated that spinal
modulation of kappa tone bi-direction-
ally modulates itch. These findings pro-
vide a mechanism by which k-opioid
agonists may selectively inhibit itch.
Henning Holle from the University of
Hull presented his study on the mechan-
ism of contagious itch and demon-
strated neuroimaging and behavioral
evidence for insular-mediated sharing
of affect as the mechanism underlying
contagious itch.
Herman O. Handwerker from the
Institute of Physiology, Erlangen,
presented his work on the functional
connectivity of cerebral networks invol-
ving cortical somatosensory areas, insu-
lar cortices, frontal areas, limbic
structures, thalamus, and basal ganglia
during cerebral processing of experi-
mental itch compared with pain. He
reported a higher functional connectiv-
ity during pain but regions revealing the
highest correlations were similar in both
itch and pain states, confirming the
processing of pain and itch in closely
related networks.
Vitaly Napadow from the Martinos
Center for Biomedical Imaging pre-
sented his study on 14 atopic dermatitis
patients and the susceptibility of itch to
nocebo and placebo effects. His data
suggest that when subjects perceive
nocebo-induced itch, the prefrontal
and striatal circuitry activated by real
allergen is also activated.
Andrea Evers from Radboud Univer-
sity Medical Centre presented evidence
on the psychophysiological similarities
and differences between itch and pain
and the implication of therapeutic stra-
tegies using placebo mechanisms for
chronic itch and pain.
Experimental itch models
Robert LaMotte from Yale presented
work on chemically elicited biological
measurements in mice and how to
identify whether they relate to itch or
to other sensory qualities. He has devel-
oped an intricate and powerful technol-
ogy that allows for stimulation of
sensory nerves in the skin while directly
visualizing them, and recording from
their cell bodies in the DRG in vivo.
Thiery Olivry, a veterinary dermatol-
ogy researcher from North Carolina
State University, demonstrated that ato-
pic dermatitis in dogs closely mimics
atopic dermatitis in people. He dis-
cussed this large animal model and
demonstrated that canines sensitized to
allergens provide a powerful model of
atopic dermatitis and thus can be used
as a proxy for the human condition.
Clinical aspects
The burden itch was a prominent feature
of the meeting. Jacek C. Szepietowski
from Wroclaw Medical University and
Thomas Mettang from the German
Clinic for Diagnostics, Wiesbaden, sug-
gested the establishment of a new work-
ing group of clinicians and scientists for
the study of uremic pruritus. Despite the
high prevalence of itch in chronic kid-
ney disease, uremic pruritus remains an
unresolved problem and its contribution
to patient suffering continues to be
under appreciated.
Suephy Chen from Emory University
reviewed the prevalence of itch and
discussed the methodology to measure
the burden of itch. Florence Dalgard
from the University of Oslow, presented
the results of her study on patients from
dermatology clinics in 13 European
countries to assess the burden of itch.
She reported that itch had a large impact
on the quality of life of affected patients
and that they were more depressed (13
vs. 5%) and experienced more anxiety
(21 vs. 12%) compared with controls.
David Roblin from Creabilis, a bio-
technology start-up, presented a study
on 160 psoriasis patients, of whom
97.5% had itch. Itch in psoriasis is
underappreciated and despite the nega-
tive effect of itch on the quality of life of
psoriasis patients, there are no available
therapeutics that target this aspect of the
condition.
Cholestatic itch was also discussed
extensively, and mouse models are
being developed. Nora Bergasa from
the Metropolitan Hospital Center, New
York, reviewed the itch of cholestasis
and discussed the relevance of proposed
mechanisms of cholestatic itch. These
mechanisms included central opioider-
gic tone, GRP, the bile acid receptor
TGR5, and autotaxin activity. Majede-
line Belghiti from Miguel Hernandez
University discussed the role of mesen-
teric mast cell degranulation, transient
receptor potential channel V1, and
protease-activated receptor-2 in a bile
duct–ligated rat model of liver disease.
Leigh Nattkemper from Temple Uni-
versity presented her study on the per-
ipheral role of IL-31 in cutaneous T-cell
lymphoma patients. IL-31 levels are
elevated in epidermal nerve fibers and
at the dermoepidermal junction of these
patients and correlate with the severity
of itch in these patients. Targeting IL-31
with mAbs is an active area of investiga-
tion and we await preliminary clinical
studies in this area.
Itch treatments
Sonja Sta¨nder from University Hospital,
Mu¨nster presented an update on the
antipruritic effects of aprepitant, a neuro-
kinin-1 receptor antagonist. She
reported significant itch reduction in
62 patients treated with aprepitant with
pruritus of various origins. Aprepitant
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therapy is associated with a decreased
number of CD5- (cluster of differentia-
tion 5), CD25-, and IL-17-positive T
lymphocytes in skin biopsies.
Charley Merrill from Mitsubishi
Tanabe Pharma presented the ongoing
investigations on nalfurafine, a centrally
active k-opioid agonist, for the treat-
ment of uremic itch in subjects with
chronic kidney disease receiving hemo-
dialysis. This drug is approved for clin-
ical use in Japan and is a part of ongoing
trials in the United States and Europe.
Contrasting findings were set up when
Mitsutoshi Tominaga from Juntendo
University in Chiba noted that H4
antagonists were not effective in a
mouse model of atopic dermatitis,
whereas Robin Thurmond from Janssen
Research & Development, San Diego,
presented data that histamine 4 receptor
(H4R) antagonism was helpful in
treating itch in human atopic dermatitis.
He discussed JNJ-39758979, a potent
oral H4R antagonist. Although clinically
effective, off-target effects prevented
further development of this specific
compound, but antagonists of a different
class should be effective.
Awards
IFSI’s Clinical Research award was
given to Henning Holle for his work
on auditory modulation of itch. The
Basic Research award was provided
to Adam Kardon in the laboratory of
Sarah Ross for his work demonstrating
that dynorphin acts as a neuromodulator
to inhibit itch in the spinal cord, thus
providing a mechanism by which
k-opioid agonists reduce the sensation
of itch. The Handwerker Prize was
awarded jointly to Sarah Wilson and
Lydia The working in the Bautista lab for
their laboratory studies on TSLP.
Summary
All aspects of the field of itch, from basic
science to quality of life to therapeutics,
are moving rapidly. Attendees are already
looking forward to the next con-
gress in Nara, Japan, in the fall of 2015.
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*The 7th World Congress on Itch was held in
Boston in September 2013.
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